Cited by 252IgG4-Related and Inflammatory DiseasesPancreatitis Pathology and TreatmentPancreatic and Hepatic Oncology Research

European Guideline on IgG4-related digestive disease - UEG and SGF evidence-based recommendations

Open access
Löhr, J‐Matthias, Beuers, Ulrich, Vujasinovic, Miroslav, Alvaro, Domenico, Frøkjær, Jens Brøndum, Buttgereit, Frank, Capurso, Gabriele, Culver, Emma L +28 more·2020·United European Gastroenterology Journal

Abstract

The overall objective of these guidelines is to provide evidence‐based recommendations for the diagnosis and management of immunoglobulin G4 (IgG4)‐related digestive disease in adults and children. IgG4‐related digestive disease can be diagnosed only with a comprehensive work‐up that includes histology, organ morphology at imaging, serology, search for other organ involvement, and response to glucocorticoid treatment. Indications for treatment are symptomatic patients with obstructive jaundice, abdominal pain, posterior pancreatic pain, and involvement of extra‐pancreatic digestive organs, including IgG4‐related cholangitis. Treatment with glucocorticoids should be weight‐based and initiated at a dose of 0.6–0.8 mg/kg body weight/day orally (typical starting dose 30‐40 mg/day prednisone equivalent) for 1 month to induce remission and then be tapered within two additional months. Response to initial treatment should be assessed at week 2–4 with clinical, biochemical and morphological markers. Maintenance treatment with glucocorticoids should be considered in multi‐organ disease or history of relapse. If there is no change in disease activity and burden within 3 months, the diagnosis should be reconsidered. If the disease relapsed during the 3 months of treatment, immunosuppressive drugs should be added.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/2050640620934911

Cites

232 of 232 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Sclerosing cholangitis spans several different aetiologies converging on final common pathways leading to fibrosis and strictures of the intra- and extrahepatic bile ducts, often with cholestasis and complications related to bile duct obstruction.

    “Sclerosing cholangitis spans several different aetiologies converging on final common pathways leading to a clinicopathologic presentation of fibrosis and strictures of the intraand extrahepatic bile ducts, often with concomitant cholestasis and other complications related to bile duct obstruction.[1][2][3]”
  • IgG4-related cholangitis, like PSC, is associated with biliary strictures, elevated serum markers of cholestasis, elevated serum IgG4 and similar clinical signs and symptoms; thus IRC and PSC may be very difficult to distinguish.

    “Among these, IRC, like PSC, is associated with biliary strictures, elevated serum markers of cholestasis, elevated serum IgG4 and similar clinical signs and symptoms; thus, IRC and PSC may be very difficult to distinguish.3”
  • In studies of IRC, the rate of corticosteroid response ranged from 62 to 100% and the relapse rate during tapering or after withdrawal was 30%.

    “the rate of corticosteroid response ranged from 62 to 100% and the relapse rate as defined by biochemical and/or imaging findings during tapering or after withdrawal was 30%. 3”
  • Treatment response to corticosteroids is regarded as a major diagnostic criterion for IRC.

    “Treatment response to corticosteroids is regarded as a major diagnostic criterion for IRC.3,39”
  • The vast majority of patients with IRC are clinical, biochemical and cholangiographic responders.

    “The vast majority of patients with IRC are clinical, biochemical and cholangiographic responders.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

1 retracted

Flagged first, then by citations

2 of the 234 references couldn’t be matched to a known paper.

Research works printed but not linked: 3

  1. Kl€ oppel G, Lu¨ttges J, L€ ohr M, et al. Autoimmune pan- creatitis: Pathological, clinical, and immunological fea- tures. Pancreas 2003; 27: 14-19.
  2. Matsubayashi H, Uesaka K, Sugiura T, et al. IgG4- related sclerosing cholangitis without obvious pancreat- ic lesion: Difficulty in differential diagnosis. J Dig Dis 2014; 15: 394-403.
  3. Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4- related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci 2014; 21: 43-50.

Cited by

Sorted by citations

Authors
Löhr, J., Beuers, U., Vujasinovic, M., Alvaro, D., Frøkjær, J. B., Buttgereit, F., Capurso, G., Culver, E. L., de‐Madaria, E., Della‐Torre, E., Detlefsen, S., Dominguez‐Muñoz, E., Czubkowski, P., Ewald, N., Frulloni, L., Gubergrits, N., Duman, D. G., Hackert, T., Iglesias‐Garcia, J., Kartalis, N., Laghi, A., Lammert, F., Lindgren, F., Okhlobystin, A., Oracz, G., Parniczky, A., Mucelli, R. M. P., Rebours, V., Rosendahl, J., Schleinitz, N., Schneider, A., van Bommel, E. F., Verbeke, C. S., Vullierme, M. P., Witt, H., & the UEG guideline working group
Affiliations
  • Department of Upper Gastrointestinal Diseases Karolinska University Hospital Stockholm Sweden and Department of Clinical Science Intervention and Technology (CLINTEC) Karolinska Institutet Stockholm Sweden
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Department of Upper Gastrointestinal Diseases Karolinska University Hospital Stockholm Sweden and Department of Medicine Huddinge Karolinska Institutet Stockholm Sweden
  • Sapienza University of Rome (IT)
  • Aalborg University Hospital (DK)
  • Charité – Universitätsmedizin Berlin (DE)
  • IRCCS San Raffaele Roma (IT)
  • John Radcliffe Hospital (GB)
  • Hospital General Universitario de Alicante Doctor Balmis (ES)
  • Vita-Salute San Raffaele University (IT)
  • Odense University Hospital (DK)
  • Department of Gastroenterology and Hepatology University Hospital of Santiago de Compostela Santiago de Compostela Spain
  • Children's Memorial Health Institute (PL)
  • Justus-Liebig-Universität Gießen (DE)
  • University of Verona (IT)
  • Donetsk National Medical University (UA)
  • Marmara University (TR)
  • Heidelberg University (DE)
  • Karolinska University Hospital (SE)
  • Azienda Ospedaliera Sant'Andrea (IT)
  • Universitätsklinikum des Saarlandes (DE)
  • Sechenov University (RU)
  • Institute for Translational Medicine Szentágothai Research Centre Medical School University of Pécs Pécs Hungary
  • Department of Abdominal Radiology Karolinska University Hospital Stockholm Sweden
  • Université Paris Cité (FR)
  • Martin Luther University Halle-Wittenberg (DE)
  • Aix-Marseille Université (FR)
  • Department of Gastroenterology and Hepatology Klinikum Bad Hersfeld Bad Hersfeld Germany
  • Department of Internal Medicine Dutch National Center of Expertise Retroperitoneal Fibrosis Albert Schweitzer hospital Dordrecht the Netherlands
  • Oslo University Hospital (NO)
  • Hôpital Beaujon (FR)
  • Else Kröner Fresenius Zentrum für Ernährungsmedizin (DE)
Venue
United European Gastroenterology Journal
Publisher
Wiley
Published
2020-07
Volume
8
Issue
6
Pages
637-666
ISSN
  • 2050-6406 (ISSN-L)
  • 2050-6414
OpenAlex
W3035831639
Cited by
252
References
234
Citations by year
2026: 40 · 2025: 43 · 2024: 46 · 2023: 40 · 2022: 36 · 2021: 38 · 2020: 8 · 2019: 1
FWCI
22.98
Type
journal article
Language
en
Open access
Locations
  • United European Gastroenterology Journal (publishedVersion)
  • PubMed Central (publishedVersion)
  • VBN Forskningsportal (Aalborg Universitet) (publishedVersion, other-oa)
  • PubMed (publishedVersion)
  • SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
  • Repository of the Academy's Library (Library of the Hungarian Academy of Sciences) (acceptedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (acceptedVersion, other-oa)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
  • VBN Forskningsportal (Aalborg Universitet) (submittedVersion, other-oa)
  • NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
  • Sage Journals Data (cc-by)
Funders
United European Gastroenterology
Topics
  • Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
Keywords
IgG4-related sclerosing cholangitis, IgG4-related pancreatitis, glucocorticoid therapy, diagnosis, treatment guidelines, recurrence, immunosuppressive therapy, obstructive jaundice, abdominal pain, pediatric patients
MeSH terms
Immunoglobulin G4-Related Disease, Adult, Body Weight, Child, Digestive System Diseases, Dose-Response Relationship, Drug, Europe, Gastroenterology, Glucocorticoids, Humans, Immunosuppressive Agents, Severity of Illness Index, Treatment Outcome, Evidence-Based Medicine, Drug Dosage Calculations, Maintenance Chemotherapy, Induction Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review